This ATCC cell line was kindly provided by Miguel Urioste Azcorra from Spanish National Cancer Research Centre (CNIO), Madrid, Spain. CT26.WT was chosen because it has the KrasG12D mutation. The cells were maintained with Dulbecco’s Modified Eagle Medium (DMEM). Cells were harvested at 80%–90% confluence using Tripsin–EDTA and replated 0.5–1 × 104 cells/cm2 with two changes of media per week until use for the experiments.
OCs lines and CT26.WT cells were cultured with 1% ZellShield (Minerva Biolabs, Berlin, Germany) and 10% Fetal Bovine Serum (FBS) and incubated at 37 °C, 5% CO2.
Copyright and License information: The Author(s) ©2022 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this
article to respond.